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AbsTrACT
background Progressive ventricular dilatation after 
intraventricular haemorrhage (IVH) in preterm infants 
has a very high risk of severe disability and death. 
Drainage, irrigation and fibrinolytic therapy (DRIFT), 
in a randomised controlled trial (RCT), reduced severe 
cognitive impairment at 2 years.
Objective To assess if the cognitive advantage of DRIFT 
seen at 2 years persisted until school age.
Participants The RCT conducted in four centres 
recruited 77 preterm infants with IVH and progressive 
ventricular enlargement over specified measurements. 
Follow- up was at 10 years of age.
Intervention Intraventricular injection of a fibrinolytic 
followed by continuous lavage, until the drainage 
was clear, and standard care consisting of control 
of expansion by lumbar punctures and if expansion 
persisted via a ventricular access device.
Primary outcome Cognitive quotient (CQ), derived 
from the British Ability Scales and Bayley III Scales, and 
survival without severe cognitive disability.
results Of the 77 children randomised, 12 died, 2 
could not be traced, 10 did not respond and 1 declined 
at 10- year follow- up. 28 in the DRIFT group and 24 
in the standard treatment group were assessed by 
examiners blinded to the intervention. The mean CQ 
score was 69.3 (SD=30.1) in the DRIFT group and 53.7 
(SD=35.7) in the standard treatment group (unadjusted 
p=0.1; adjusted p=0.01, after adjustment for the 
prespecified variables sex, birth weight and IVH grade). 
Survival without severe cognitive disability was 66% in 
the DRIFT group and 35% in the standard treatment 
group (unadjusted p=0.019; adjusted p=0.003).
Conclusion DRIFT is the first intervention for 
posthaemorrhagic ventricular dilatation to objectively 
demonstrate sustained cognitive improvement.
Trial registration number ISRCTN80286058.
InTrOduCTIOn
Intraventricular haemorrhage (IVH) remains one 
of the most serious complications of preterm birth. 
It is the most common cause of brain injury in 
preterm infants1 and the primary risk factor for 
special educational needs at school age.2 Large 
IVHs cause a progressive obliterative arachnoiditis, 
disturbing the flow and absorption of cerebrospinal 
fluid (CSF),3 thereby causing posthaemorrhagic 
ventricular dilatation (PHVD). Around 70% of 
very low birthweight (VLBW) infants with severe- 
grade IVH develop persistent PHVD, and a third 
of infants with PHVD require surgical drainage of 
CSF by permanent ventriculoperitoneal (VP) shunt 
to control ventricular expansion.4 The raised pres-
sure, distortion, and neurotoxic and inflammatory 
effects of blood in the ventricular system cause 
progressive brain injury and subsequent neurodis-
ability, which is often severe.5 Infants under 1000 g 
who went on to shunt surgery had very high rates of 
motor, cognitive and multiple disabilities.6
A European survey found the most common 
approach in VLBW infants with PHVD was 
repeated lumbar punctures (LPs) followed by inser-
tion of a ventricular access device (VAD) to enable 
regular tapping of CSF and control of ventricular 
expansion. If the need for tapping persists, a VP 
What is already known on this topic?
 ► Progressive ventricular dilatation after 
intraventricular haemorrhage (IVH) in preterm 
infants has a very high risk of severe disability 
and death.
 ► Several interventions tested in randomised 
controlled trials (RCTs) have failed to reduce 
neurodisability in preterm infants with IVH and 
posthaemorrhagic ventricular dilatation (PHVD).
 ► Drainage, irrigation and fibrinolytic therapy 
(DRIFT), in an RCT, reduced severe cognitive 
disability at 2 years of age.
What this study adds?
 ► DRIFT achieved a sustained reduction of severe 
cognitive disability at school age, the first 
intervention for IVH with PHVD to objectively 
demonstrate long- term benefit.
 ► The findings are applicable to preterm infants 
with PHVD in well- resourced healthcare 
settings.
 ► The proof of principle that secondary brain 
injury is reduced by washing away the harmful 
debris of IVH in a controlled way has been 
established.
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shunt is then inserted weeks later when the blood and protein 
have cleared from the CSF and the infant’s weight has reached 
2 kg.7 VAD and VP shunt insertion are associated with significant 
risk of infection and malfunction.8
Several interventions tested in randomised controlled trials 
(RCTs) have failed to reduce neurodisability rates as a result 
of PHVD.9 Drainage, irrigation and fibrinolytic therapy 
(DRIFT)10–12 was developed due to the unsatisfactory results of 
other treatments. The objective is to remove proinflammatory 
cytokines, free iron and old blood from within the ventricles, 
and reduce both pressure and distortion.
The DRIFT RCT was conducted between 2003 and 2006.10 
There were no differences in the need for VP shunt or death 
at 6 months. However, at 2 years post- term, severe disability or 
death was significantly reduced in the DRIFT group.11
We have followed up these patients at 10 years of age to 
determine if the cognitive advantage seen with DRIFT at 2 years 
continued through to school age. The secondary objectives were 
to assess long- term visual, sensorimotor function and emotional/
behavioural difficulties. We hypothesised that DRIFT would 
reduce severe cognitive disability at school age.
MeThOds
Initial study
DRIFT is a surgical approach developed in Bristol. Temporary 
frontal and left occipital ventricular catheters are inserted under 
anaesthesia. Tissue plasminogen activator is injected intraventric-
ularly at a subsystemic dose. The ventricles are irrigated by artifi-
cial CSF through a frontal catheter. When the ventricular system 
has been cleared of blood and debris, catheters are removed.
After feasibility testing showed DRIFT was technically possible 
and promising,12 the DRIFT RCT started recruiting in 2003.10
Eligible babies were preterm, had had IVH and had expanded 
cerebral ventricles over predetermined measurements. In total 77 
babies (54 in Bristol (UK), 20 in Katowice (Poland), 2 in Glasgow 
(UK) and 1 in Bergen (Norway)) were randomised during 2003–
2006 to either DRIFT or standard treatment, which consisted 
of LPs to control excessive expansion and pressure symptoms. 
If repeated LPs were needed, a VAD was surgically inserted to 
facilitate tapping of CSF. Every infant randomised to DRIFT 
received DRIFT, and no infant in the standard treatment group 
received DRIFT. At the time of intervention it was not possible 
to blind clinicians; however, all subsequent researchers were 
unaware of treatment group allocation. Full details of the trial 
have been published.10
Of the 77 babies randomised, 69 survived until 2 years. Severe 
cognitive disability (Bayley Mental Development Index (MDI) 3 
SD below the mean) was 31% in the DRIFT group and 59% in 
the standard treatment group (adjusted OR: 0.17 (95% CI 0.05 
to 0.57)), and the difference in median MDI score was more 
than 18 points.11
Follow-up study
The follow- up study was designed with input from children and 
parents who had taken part in the initial feasibility study. Assess-
ments consisted of cognitive, motor and visual ability, presence 
and severity of cerebral palsy (CP), and parental completion 
of a vision and behavioural inventory. Children in Poland did 
not have visual or motor assessments. All assessments were 
performed between February 2015 and April 2016. All outcome 
assessors were blinded to treatment allocation.
The primary hypothesis was whether DRIFT would reduce 
severe cognitive disability in children assessed at school age.
Imbalances in covariates affecting cognition were seen at 
randomisation and in the previous 2- year follow- up. Conse-
quently, for this work we prespecified in the statistical anal-
ysis plan adjustment for birth weight, IVH grade and sex, with 
approval by the independent National Institute for Health 
Research follow- up study steering committee (including an 
independent statistician). The secondary outcomes were also 
adjusted for age, as the follow- up ages ranged from 8 to 12 
years. Primary, secondary and exploratory analyses described 
here were prespecified in the study protocol (https://www. jour-
nalslibrary. nihr. ac. uk/ programmes/ hta/ 123561/#/).
The follow- up study was funded by the National Institute of 
Health Research (Health Technology Assessment), for which a 
report/monograph has been published in full.13
Primary outcome
Cognitive disability at school age
Cognitive assessments were undertaken by two child psychol-
ogists. The British Ability Scales- III was used for children with 
a developmental age of 3+ years.14 For children who did not 
meet this threshold, the Bayley Scales of Infant and Toddler 
Development- III was administered.15 The final scores were in 
the format of a cognitive quotient (CQ; from 0 to 100+), based 
on the division of their developmental age equivalent by their 
actual age (multiplied by 100).16 The primary analysis was based 
on the cognitive scores of surviving children, although a sensi-
tivity analysis was performed including children who died (due 
to disability), where the CQ for these children could reasonably 
be assumed to be 0. Several sensitivity analyses were carried out, 
including the use of a binary outcome (death or severe cognitive 
disability), where all deaths over the 10- year period and deaths 
post 2 years that were deemed related to disability were included 
as negative outcomes. For patients who died after the 2- year 
follow- up, where the cause of death was unknown, we assumed 
that their death was due to disability if they had severe disability 
at 2 years. Severe cognitive disability was defined as a cognitive 
score below 3 SD of the population mean.
secondary outcomes
Cerebral visual function
For the main visual outcomes, parents were asked about their 
child’s vision, describing them as ‘No concerns’, ‘Normal with 
Correction’, ‘Useful but not fully correctable’ and ‘Blind or 
perceives light only’. A binary outcome was created that split 
these into good visual outcome (no concerns/normal with correc-
tion) and poor visual outcome (useful but not fully correctable/
blind or perceives light only). Parents were asked 23 questions 
about their child’s visual behaviour from an inventory identi-
fying examples of vision processing impairment.17 A mean score 
was created.
Sensorimotor disability
Children were assessed using the Movement Assessment 
Battery for Children-2 (MABC-2) by a paediatric physiother-
apist.18 The presence and severity of CP were also compared 
between the two groups according to the recommendations of 
the Surveillance of Cerebral Palsy in Europe, using the Gross 
Motor Function Classification System.19 All children with 
CP were classified as having severe sensorimotor disability, 
moderate if MABC-2 scores were between 57 and 67, and none 
if MABC-2 >67.
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Figure 1 Drainage, irrigation and fibrinolytic therapy (DRIFT) 
participant flow.
Emotional/behavioural function
Parents were asked to complete the Strengths and Difficulties 
Questionnaire (SDQ), which assesses child behaviour. The final 
score classifies the child as having normal or abnormal behaviour.20
Power calculation
Based on the effect size of DRIFT treatment on severe cognitive 
disability at 2 years,11 a two- group continuity- corrected χ2 test 
with 5% two- sided significance level would have 80% power 
to detect the difference in severe cognitive disability between a 
standard treatment group proportion of 59% and OR of 0.17 
(ie, an intervention proportion of 19.7%) when the sample size 
in each group is 28. Assuming 90% follow- up rate, 60 infants (30 
in each group) would have 97% power (with an alpha of 5%) to 
detect a mean cognitive score difference of 1 SD (commonly 15 
points) between the DRIFT and the standard treatment group.
statistical analysis
All statistical analyses were performed using STATA V.14.1 soft-
ware. All p values were two- sided and considered significant if 
p<0.05.
resulTs
study population and participant flow
Figure 1 shows the layout of the trial and the different levels 
of dropout and analyses. Seventy- seven babies were originally 
recruited to either receive DRIFT (39 infants) or standard treat-
ment (38 infants).
At 2- year follow- up there had been eight deaths due to 
complications of prematurity, but no loss to follow- up. Approx-
imately 8 years later (between September 2015 and April 2016), 
parents were contacted and asked to take part in the 10- year 
follow- up study. Two patients (both in the DRIFT group) could 
not be traced. This left 67 patients where the survival status was 
known. Of these, there were 2 deaths in the DRIFT group, 2 
deaths in the standard treatment group (all 4 were associated 
with severe disability), 1 patient who declined to take part in 
the follow- up (standard treatment group) and 10 who gave no 
response (4 DRIFT, 6 standard), leaving 52 available for assess-
ment (28 DRIFT, 24 standard). For the primary outcome we 
obtained 51 children’s CQ score: 27 in the DRIFT group and 24 
in the standard treatment group.
baseline data
For the 52 children available for follow- up assessments at 
10 years, there were imbalances seen in sex and birth weight 
(table 1). In the DRIFT group, 22 (79%) children were male, 
whereas in the standard treatment group 63% were male. The 
mean birth weight was 1322 g in the standard treatment group 
and 1102 g in the DRIFT group.
Primary analyses
Primary outcomes
CQ scores were relatively normally distributed with an overall 
mean of 62.0 and a median of 68.7. Figure 2 shows the distri-
bution of scores by treatment allocation. Children receiving 
DRIFT had a mean quotient score of 69.3 (median 72.3) vs 
53.7 (median 44.6) for children receiving standard treatment. 
The maximum CQ score was 130.6 (DRIFT group), indicating 
a cognitive ability that is 30% higher than we would expect to 
see at their age (developmental age 30% higher than actual age). 
The highest CQ score achieved in the standard treatment group 
was 107.2. Only two children had CQ score below 30 (profound 
cognitive disability) in the DRIFT group, compared with seven 
children in the standard treatment group.
Table 2 shows the results of the primary analysis, including and 
excluding deaths. Given the larger than expected attrition/death 
rate, precision was lower than predicted, exacerbated further by 
the large SD for the CQ. Despite this, the results are in parallel 
with those at 2 years, with crude estimates giving weak evidence 
that the DRIFT intervention increases cognitive ability at 10 
years (p=0.096). After adjusting for the prespecified variables 
sex, birth weight and IVH grade, this evidence was strengthened 
and indicated that children in the DRIFT group had, on average, 
CQ scores 23.47 points higher than those who received stan-
dard treatment (p=0.009). This translates into a developmental 
cognitive advantage of 2.5 years (95% CI 0.5 to 4.4).
Sensitivity analyses
The binary outcome used in the 2- year follow- up was repli-
cated at 10 years, resulting in 21 of 32 (66%) patients surviving 
without severe cognitive disability in the DRIFT group compared 
with 11 of 31 (35%) patients in the standard treatment group 
(adjusted OR 7.69 (1.96 to 30.11), p=0.003). Survival without 
severe cognitive disability (removing deaths before 2 years) also 
gave very similar results to the continuous CQ outcome (unad-
justed OR 3.58 (1.16 to 11.04), p=0.026; adjusted OR 9.96 
(2.12 to 46.67), p=0.004). The number needed to treat (NNT) 
to prevent one death or case of severe cognitive disability was 
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Mean (sd) or n (%) Mean (sd) or n (%)







Katowice, Poland 3 (11%) 4 (17%)
Glasgow, UK 1 (4%) 1 (4%)
Bergen, Norway 1 (4%) 0 (0%)
Sociodemographics at birth
Age at randomisation (days) 28 18.68 (5.00) 24 19.17 (4.53)
Sex: male* 28 22 (79%) 24 15 (63%)
Clinical characteristics at birth
Birth weight (g)* 28 1101.89 (335.54) 24 1322.46 (534.68)
Gestation (weeks) 28 27.64 (2.56) 24 28.50 (3.05)
Grade of IVH: 4 28 14 (50%) 24 11 (46%)
Maternal age at birth 14 28.50 (6.99) 12 28.17 (6.32)
Median IMD 2010, postcode 
at birth† (IQR)
18 26.7 (8.2–36.5) 18 27.6 (11.2–45.8)
Measures at 2 years
Experienced second IVH* 28 8 (29%) 24 3 (13%)
VP shunt 28 11 (39%) 24 8 (33%)
Ventricular access device* 28 13 (46%) 24 19 (79%)
Measures at 10 years
Age at 10- year assessment 
(years)
28 10.56 (1.07) 24 10.76 (1.06)
Weight (kg) 28 35.41 (10.05) 23 34.73 (10.51)
Height (cm) 28 139.09 (12.22) 23 142.26 (11.34)
Head circumference (cm) 28 52.88 (2.53) 23 52.00 (3.43)
Maternal education*





Further education 6 (21%) 5 (22%)
University degree 12 (43%) 7 (30%)
*Difference of 10%/0.5 SD or higher between the groups.
†English Index of Multiple Deprivation (IMD) 2010 scores, UK Data Service Census Support (http://geoconvert.mimas.ac.uk/). Higher scores indicate higher levels of deprivation. IMD based on the 
children’s home postcode at birth for those residing in England only.
DRIFT, drainage, irrigation and fibrinolytic therapy; IVH, intraventricular haemorrhage; VP, ventriculoperitoneal.
3. More details on cause of death and sensitivity analyses are 
included in the online supplementary appendix.
secondary outcomes
Parent-reported vision
A higher proportion of children from the DRIFT group had 
‘good visual outcome’, but there was high variance and this was 
not statistically significant (adjusted OR 3.73 (95% CI 0.66 to 
21.14), p=0.136). A small difference was found in the question 
inventory mean score (adjusted mean difference −0.12 (95% CI 
−0.47 to 0.24), p=0.502) (table 3).
Sensorimotor disability
There was no difference in sensorimotor disability, with severe, 
moderate and no sensorimotor disability percentages of 85%, 
7% and 7% for patients in the DRIFT group, respectively, 
compared with 76%, 10% and 14% in the standard treatment 
group (adjusted OR 3.66 (0.33 to 40.34), p=0.290). There was 
no significant difference in the percentages with CP or severity 
of CP between the two groups (61% vs 58% for DRIFT and 
standard treatment, respectively) (table 3).
Emotional/behavioural function
For the SDQ total score, higher values indicated more 
‘abnormal’ behaviour. There was no difference between the two 
groups (adjusted mean difference 2.01 (95% CI −2.78 to 6.81), 
p=0.401).
sensitivity/subgroup analyses
Additional sensitivity analyses, described in the online supple-
mentary appendix, were carried out that include multiple impu-
tation and adjustment for centre, all of which were consistent 
with the primary outcome (online supplementary eTable 1). We 
did not find any subgroup effects to suggest that DRIFT was 
more effective in certain subgroups, although it needs to be 
emphasised that we were not powered to detect any differences 
between subgroups (online supplementary eTable 2). Maternal 
educational attainment was imbalanced at 10 years, with a 
greater proportion of mothers in the DRIFT group accessing 
university education (table 1). In a post- hoc sensitivity analysis, 
we adjusted for maternal level of education (online supplemen-
tary eTable 1). Adjustment for maternal education (measured 
10 years after randomisation) resulted in a slight attenuation of 
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Figure 2 Cognitive quotient, by trial allocation. The box plot indicates 
the median (central blue line in the box), mean (red dashed line), 25th 
percentile (bottom line of the box), 75th percentile (top line of the box), 
and the whiskers for the minimum and maximum values (excluding 
outliers). The diamonds beyond these whiskers are the outliers, which 
are observations that lie at an abnormal distance from other values. 
Outliers are defined as those higher than 1.5× IQR+75th percentile or 
lower than 25th percentile−1.5× IQR. DRIFT, drainage, irrigation and 
fibrinolytic therapy.





Mean (sd) or n (%)
standard
Mean (sd) or n (%)
Crude difference (95% CI), p 
value
Adjusted difference (95% CI), 
p value*
Primary outcome
Cognitive ability quotient 27:24 69.33 (30.06) 53.68 (35.70) 15.65 (−2.86 to 34.16), 0.096† 23.47 (6.23 to 40.71), 0.009†
Sensitivity analyses
Cognitive ability quotient‡ 29:26 64.55 (34.04) 49.55 (37.22) 15.00 (−4.28 to 34.27), 0.125† 22.33 (4.77 to 39.89), 0.014†
Alive and without severe cognitive disability§ 29:26 21 (72%) 11 (42%) 3.58 (1.16 to 11.04), 0.026¶ 9.96 (2.12 to 46.67), 0.004¶
Alive and without severe cognitive disability** 32:31 21 (66%) 11 (35%) 3.47 (1.23 to 9.78), 0.019¶ 7.69 (1.96 to 30.11), 0.003¶
*Adjusted for sex, birth weight and grade of IVH.
†Linear regression (difference in means).
‡Giving children who have died post 2 years a score of 0.
§Including all 4 deaths after 2 years as a negative outcome.
¶Logistic regression (OR).
**Including all 12 deaths as a negative outcome (akin to the study results at 2 years).
DRIFT, drainage, irrigation and fibrinolytic therapy; IVH, intraventricular haemorrhage.
effect size with an 11.5 point CQ advantage (unadjusted p=0.2) 
and a significant 20.1 point CQ advantage after adjustment 
for the prespecified variables sex, birth weight and IVH grade 
(adjusted p=0.02) with DRIFT.
Additional data from parental history were available regarding 
special education needs in children. After adjustment, those in 
the DRIFT group showed a trend towards lower odds of special 
school attendance in the preceding 12 months compared with 
those in the standard treatment group (OR 0.27 (95% CI 0.07 
to 1.05), p=0.059). This suggests that there may be a benefit in 
terms of educational attainment from DRIFT treatment.
dIsCussIOn
summary of findings
DRIFT treatment of preterm infants with severe IVH and PHVD 
improves cognitive ability at 10- year follow- up when taking into 
account birth weight, IVH grade and sex. There were no signifi-
cant differences in the secondary outcomes: parent- reported visual 
impairment, sensorimotor disability or emotional/behavioural 
difficulties. Surrogate markers of functional ability (special 
education) showed a trend towards long- term benefits of DRIFT 
treatment.
Crucially, infants who received DRIFT were almost twice as 
likely to survive without severe cognitive disability than those who 
received standard treatment. While the CIs were wide, the point 
estimate suggests that the NNT for DRIFT to prevent one death or 
one case of severe cognitive disability was 3.
strengths and limitations
The strength of this study is the long- term follow- up to middle- 
school age, which strengthens the validity of conclusions around 
cognitive ability. In neonatal interventional trials, long- term 
follow- up is challenging as families move. It requires active buy- in 
from both children and their parents and a significant time commit-
ment for families. Where a significant proportion of survivors have 
severe neurodisabilities, as seen with PHVD, the logistics to return 
for follow- up assessment become even more challenging.
Where children have a very wide range of abilities, precise 
cognitive scoring becomes a significant challenge. Our approach to 
cognitive assessment achieved CQ in children of all abilities. Inclu-
sion of special education as a pragmatic post- hoc outcome gives 
some idea of the likely gains going forward into an independent 
adulthood.
Ongoing family involvement and the organisation of the 
British National Health Service ensured a very high follow- up 
rate at school age in the UK. Only two patients had an unknown 
survival status at 10 years, and best and worst case scenarios 
were also explored (online supplementary eTable 1).
While the higher CQ score results were apparent in all analyses, 
the effect did not reach conventional levels of statistical signifi-
cance in the unadjusted analyses of mean CQ scores. However, 
important characteristics were unbalanced at randomisation and at 
10- year follow- up, with a larger proportion of higher risk cases in 
the DRIFT group. In the DRIFT group, infants were significantly 
smaller, less mature, with greater proportion of male and had more 
severe- grade IVH, and consequently adjustments for the imbalances 
were prespecified in the analysis plan. Of note, the association seen 
in the binary outcome (survival without severe cognitive disability) 
was clear in the unadjusted and adjusted analyses. Another limita-
tion was that maternal education was not collected at birth, and 
our use of a proxy measure of maternal education at 10 years is 
difficult to interpret, especially if educational attainment was 
gained after baseline. We have adjusted for maternal educational 
level, which may be a useful proxy but may not give a full picture 
of family functioning. Details about use of rehabilitative services 
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n (%) or mean (sd)
standard
n (%) or mean (sd)
unadjusted difference
(95% CI), p value
Adjusted difference*
(95% CI), p value
Parent- reported visual function
Good vision 27:24 23 (85%) 17 (71%) 2.37 (0.60 to 9.40), 0.22† 3.73 (0.66 to 21.14), 0.14†
Questionnaire mean score 28:21 4.50 (0.70) 4.65 (0.38) −0.15 (−0.49 to 0.19), 0.38‡ −0.12 (−0.47 to 0.24), 0.50‡
Sensorimotor disability
None 2 (7%) 3 (14%)     
Moderate 27:21 2 (7%) 2 (10%) 0.55 (0.13 to 2.34), 0.42§ 3.66 (0.33 to 40.34), 0.29§
Severe 23 (85%) 16 (76%)     
Cerebral palsy
Diagnosed with cerebral palsy (%) 28:24 17 (61%) 14 (58%) 1.10 (0.36 to 3.35), 0.86† 0.37 (0.07 to 2.00), 0.25†
  GMFCS level 1 7 (41%) 5 (36%)     
  GMFCS level 2 4 (24%) 3 (21%)     
  GMFCS level 3 2 (12%) 0 (0%)     
  GMFCS level 4 0 (0%) 2 (14%)     
  GMFCS level 5 4 (24%) 4 (29%)     
Ambulant¶ 11 (65%) 8 (57%) 1.38 (0.32 to 5.88), 0.67 1.32 (0.24 to 7.25), 0.75
Strengths and Difficulties Questionnaire
Total score 28:22 14.89 (8.48) 13.36 (6.59) 1.53 (−2.89 to 5.94), 0.49‡ 2.01 (−2.78 to 6.81), 0.40‡
*Adjusted for age, sex, birth weight and grade of IVH.
†Logistic regression (OR).
‡Linear regression (difference in means).
§Ordinal logistic regression (OR per increase in category).
¶Children with cerebral palsy were categorised as ambulant (GMFCS level 1–2) or non- ambulant (GMFCS level 3–5).
DRIFT, drainage, irrigation and fibrinolytic therapy; GMFCS, Gross Motor Function Classification System; IVH, intraventricular haemorrhage.
were not collected as these data are not formally available in the 
UK and it was not reasonable to expect families to reliably recall 
the type and level of intervention over a period of 9–10 years after 
discharge from the neonatal unit.
The main limitation is reduced precision of results due to the 
size of the trial. This intervention was innovative and invasive, and 
for safety reasons the trial had stringent stopping criteria which 
limited the achieved sample size. This unfortunately resulted in a 
lower sample size than was required to give 80% power for the 
primary outcome (CQ), and consequently wide CIs around the 
point estimates for both the continuous and binary outcomes.
Interpretation of results
Preterm infants with severe IVH and PHVD have a very high 
reported rate of neurodisability. The National Institute of Child 
Health and Development study, the largest of its kind, studied 
preterm infants with severe IVH (grade 3 and 4), of whom 
almost 25% had PHVD.6 At 18–22 months corrected age, 68% 
of children with severe- grade IVH and PHVD were reported 
to have moderate cognitive impairment (MDI below 2 SD) and 
41% had severe cognitive impairment (MDI below 3 SD). The 
presence of haemorrhagic parenchymal infarction, in addition 
to PHVD, increased the risk of CP to between 80% and 90%.
In our study follow- up at 10 years found similar severe cognitive 
disability rates: 52% in the standard treatment arm. The propor-
tion of children with severe cognitive disability with DRIFT was 
21%. This paper further supports that the DRIFT process improves 
outcome in this group of infants, with evidence of improvement 
in the number of infants with a very low cognitive score and an 
overall increase in the mean cognitive score. With the precision 
available in this trial, we were unable to identify if DRIFT has a 
disproportionate effect across this range. Children who received 
DRIFT were also more likely to attend mainstream schools. The 
reduction in severe cognitive disability seen with this intervention 
is likely to translate into the ability to lead more independent lives 
into adulthood.
DRIFT had an effect on cognition but did not appear to improve 
motor function. Of the children, 50% (DRIFT) and 46% (stan-
dard care) had haemorrhagic parenchymal infarctions (grade 
4 IVH). The most likely explanation for the disproportionate 
effect on cognition is that simple irrigation, although effective at 
reducing secondary global neurotoxicity and damage to cortical 
and subcortical tissue, is not sufficient to promote tissue regener-
ation in critical motor tracts after significant parenchymal infarc-
tion. Motor outcome is likely primarily determined by the initial 
amount of acute tissue injury/loss incurred by a large focal haemor-
rhagic parenchymal infarction. There was a strong trend towards 
improved visual function, but this did not reach statistical signifi-
cance due to marked variability of outcome.
Implications for practice in the context of current standard 
treatments and other research
DRIFT is the first and only intervention for PHVD in preterm 
infants to demonstrate long- term benefit in an RCT. The proof 
of principle that secondary brain injury is reduced by washing 
away the harmful debris of IVH in a controlled way with DRIFT 
has been established. This is a hugely promising development in 
a group of infants with a high rate of long- term neurodisability.
Existing standard treatment with relief of intracranial pres-
sure by CSF drainage through LP or insertion of a VAD results 
in worse outcomes than those seen with DRIFT. The recently 
published data from the Early vs Late Ventricular Intervention 
Study (ISRCTN43171322), a multicentre RCT comparing two 
treatment thresholds for VAD insertion after PHVD, have not 
revealed benefits from commencing standard treatment at a 
lower threshold. The short- term outcomes show no benefit from 
the lower threshold and significantly more invasive procedures.21 
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There was no significant difference in mortality or neurodevel-
opmental outcome at 2 years of age.22
Alternative surgical interventions are being tested. A feasi-
bility study of ventricular endoscopic lavage demonstrated fewer 
short- term complications and need for VP shunts in comparison 
with standard treatment in historical controls. However, there 
is a lack of long- term data on outcomes from these children.23
DRIFT then offers the only proven option for improving 
outcomes after PHVD in preterm infants. The aim of DRIFT is 
to improve neurodevelopmental outcomes, and therefore while 
there appears to be a net benefit to the infant this would need 
to be balanced with the potential risks (eg, infection, secondary 
haemorrhage and rapid fluctuation of intracranial pressure). 
The expertise required for skilled insertion of two ventricular 
catheters into a tiny infant, followed by prolonged accurate 
monitoring of intracranial pressure, adjustment of drainage rate 
and detection of catheter blockage, all done with immaculate 
aseptic technique, is significant. The complexity, risks and rarity 
of candidates are roughly comparable with those of extracorpo-
real membrane oxygenation, and implementation of DRIFT as 
a clinical service would likely require a small number of highly 
specialised centres in order to achieve adequate throughput of 
patients to develop and maintain such expertise, for example, 
four or five for the UK. For comparison, Haukeland Hospital 
in Bergen is the only centre in Norway (population 5.3 million) 
providing DRIFT service to referred infants.
COnClusIOns
PHVD is associated with high levels of severe neurodisability 
with marked detrimental effect on cognitive function. DRIFT is 
the first intervention to objectively demonstrate sustained cogni-
tive improvement in preterm infants with PHVD that is sustained 
into middle- school age. Although invasive and technically 
demanding, this treatment approach provides clear improve-
ments in outcome and deserves detailed further evaluation.
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